IRVINE, Calif., March 30, 2024 (GLOBE NEWSWIRE) — Concerning a launch issued below the identical headline on March 29, 2024 by AEON Biopharma, Inc. (NYSE: AEON; AEON.WS), please observe that within the first paragraph it incorrectly referenced March 29, 2024 because the Redemption Date. The Redemption Date is April 29, 2024. March 29, 2024 is the date on which the discover of redemption was delivered to warrant holders. The corrected launch follows:
AEON Biopharma, Inc. (NYSE: AEON; AEON.WS) (“AEON” or “the Firm”), a clinical-stage biopharmaceutical firm centered on growing a proprietary botulinum toxin complicated for the therapy of a number of debilitating medical situations, as we speak introduced that the Firm will redeem all of its excellent warrants (the “Public Warrants”) to buy shares of the Firm’s Class A typical inventory, par worth $0.0001 per share (the “Widespread Inventory”), that had been issued below the Warrant Settlement, dated February 8, 2021 (the “Warrant Settlement”), by and between the Firm and Continental Inventory Switch & Belief Firm, as warrant agent (the “Warrant Agent”), as a part of the models offered within the Firm’s preliminary public providing (the “IPO”), for a redemption worth of $0.10 per Public Warrant (the “Redemption Value”), that stay excellent at 5:00 p.m. New York Metropolis time on April 29, 2024 (the “Redemption Date”). Warrants to buy Widespread Inventory that had been issued below the Warrant Settlement in a non-public placement concurrently with the IPO and nonetheless held by the preliminary holders thereof or their permitted transferees should not topic to this redemption.
Beneath the phrases of the Warrant Settlement, the Firm is entitled to redeem the entire excellent Public Warrants if the final gross sales worth of the Widespread Inventory is at the least $10.00 per share on any twenty buying and selling days inside any thirty-day buying and selling interval ending on the third buying and selling day previous to the date on which a discover of redemption is given. On the path of the Firm, the Warrant Agent has delivered a discover of redemption to every of the registered holders of the excellent Public Warrants.
As well as, in accordance with the Warrant Settlement, the Firm’s board of administrators has elected to require that, upon supply of the discover of redemption, all Public Warrants are to be exercised solely on a “cashless foundation.” Accordingly, holders might now not train Public Warrants and obtain Widespread Inventory in change for cost in money of the $11.50 per warrant train worth. Any Public Warrants that stay unexercised at 5:00 p.m. New York Metropolis time on the Redemption Date might be delisted, void and now not exercisable, and the holders could have no rights with respect to these Public Warrants, besides to obtain the Redemption Value (or as in any other case described within the redemption discover for holders who maintain their Public Warrants in “avenue identify”).
The variety of shares of Widespread Inventory that every exercising warrant holder will obtain by advantage of the cashless train (as a substitute of paying the $11.50 per Public Warrant money train worth) might be calculated in accordance with the phrases of the Warrant Settlement and might be equal to the variety of shares decided by reference to the Honest Market Worth of Class A Widespread Inventory desk in Part 6.2 of the Warrant Settlement and the Redemption Honest Market Worth as of the Redemption Date. The Redemption Honest Market Worth means the amount weighted common worth of the Widespread Inventory for the ten buying and selling days instantly following the date of the discover of redemption. If any holder of Public Warrants would, after bearing in mind all of such holder’s Public Warrants exercised at one time, be entitled to obtain a fractional curiosity in a share of Widespread Inventory, the variety of shares the holder might be entitled to obtain might be rounded right down to the closest complete variety of shares.
Questions regarding redemption and train of the Public Warrants could be directed to Continental Inventory Switch & Belief Firm, 1 State Road, thirtieth Flooring, New York, New York 10004, Consideration: Compliance Division, phone quantity (212) 509-4000.
No Provide or Solicitation
This press launch shall not represent a suggestion to promote or the solicitation of a suggestion to purchase nor shall there be any supply of any of the Firm’s securities in any jurisdiction during which such supply, solicitation or sale could be illegal previous to the registration or qualification below the securities legal guidelines of any such jurisdiction.
About AEON Biopharma
AEON is a medical stage biopharmaceutical firm centered on growing its proprietary botulinum toxin complicated, ABP-450 (prabotulinumtoxinA) injection, or ABP-450, for debilitating medical situations, with an preliminary concentrate on the neurosciences market. AEON not too long ago accomplished a Part 2 examine of ABP-450 for the therapy of cervical dystonia and has an ongoing Part 2 examine of ABP-450 for the preventive therapy of continual migraine. ABP-450 is identical botulinum toxin complicated that’s presently authorized and marketed for beauty indications by Evolus below the identify Jeuveau. ABP-450 is manufactured by Daewoong in compliance with present Good Manufacturing Follow, or cGMP, in a facility that has been authorized by the U.S. Meals and Drug Administration, or the FDA, Well being Canada and European Medicines Company, or EMA. AEON has unique improvement and distribution rights for therapeutic indications of ABP-450 in the USA, Canada, the European Union, the UK, and sure different worldwide territories. The Firm has constructed a extremely skilled administration crew with particular expertise in biopharmaceutical and botulinum toxin improvement and commercialization. To be taught extra about AEON and the event of its uniquely positioned therapeutic neurotoxin, go to www.aeonbiopharma.com.
Contacts
Investor Contact:
Corey Davis, Ph.D.
LifeSci Advisors
+1 212 915 2577
cdavis@lifesciadvisors.com
Supply: AEON Biopharma
The put up CORRECTION — AEON Biopharma Publicizes Redemption of Public Warrants – TipRanks Monetary Weblog appeared first on DailyBusiness.